CLICK TO SHARE
This material may not be published, broadcast, rewritten, or redistributed. ©2022 FOX News Network, LLC. All rights reserved. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. Mutual Fund and ETF data provided by Refinitiv Lipper.
Home improvement and lifestyle expert Skip Bedell breaks down how to stick to your New Year's resolutions while staying home.
Liver tumors died off in a third of patients enrolled in a study who received immunotherapy treatment before surgery, according to Mount Sinai researchers in New York City. The study was recently published in The Lancet Gastroenterology & Hepatology.
Liver cancer is one of the deadliest and most common cancers, the study’s senior author and associate professor of medicine (hematology and medical oncology) at the Icahn School of Medicine at Mount Sinai, Dr. Thomas Marron, told Fox News in an interview.
"While we can cure it sometimes with surgery, unfortunately it often comes back—more often than most other cancers—and so one of the main reasons we did this trial was to find a way to decrease the likelihood the cancer will come back," Marron, who is also the director of the Early Phase Trials Unit at The Tisch Cancer Institute and holds a Ph.D. in Immunology, said in a release discussing the recent report.
If you don't see any comments yet, congrats! You get first comment. Be nice and have fun.
CLICK TO SHARE